vimarsana.com
Home
Live Updates
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institutes Molecular Tumor Board -November 03, 2023 at 09:16 am EDT : vimarsana.com
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board -November 03, 2023 at 09:16 am EDT
Golden, Colorado, Nov. 03, 2023 -- Theralink Technologies, Inc. , a precision oncology company with its exclusive commercial RPPA technology that can help predict which FDA-approved drug is...
Related Keywords
Chicago
,
Illinois
,
United States
,
Colorado
,
Trevor Mccartney
,
Exchange Commission
,
Inova Schar Cancer Institute
,
Gastrointestinal Cancer Program
,
Nasdaq
,
Securities Exchange
,
Holdings Inc
,
Theralink Technologies Inc
,
Globenewswire Inc
,
Schar Cancer Institute
,
Molecular Tumor Board
,
Inova Schar Molecular Tumor
,
Schar Cancer
,
Chief Executive Officer
,
Inova Molecular Tumor Board
,
Reverse Phase Protein Array
,
Securities Act
,
Securities Exchange Act
,
Merger Agreement
,
Quarterly Reports
,
Current Reports
,
Annual Reports
,
Multi Omic Data
,
Molecular Tumor Board Reveals
,
Inhibitor Resistance
,
Patient With Inflammatory Myofibroblastic
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.